Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank

Affiliations

¹ Duke University and the Duke Clinical Research Institute, Durham, NC.
² Vanderbilt University Medical Center, Nashville, TN.
³ Medical University of South Carolina, Charleston, SC.
⁴ AstraZeneca, Gaithersburg, MD.
⁵ Bayer AG, Whippany, NJ.
⁶ Daiichi Sankyo, Parsippany, NJ.
⁷ Columbia University Medical Center, New York, NY.
⁸ Nationwide Children's Hospital, Columbus, OH.
⁹ Parent Project Muscular Dystrophy, Middletown, OH.
¹⁰ Bristol-Myers Squibb, Princeton, NJ.
¹¹ Albert Einstein College of Medicine, New York, NY.
¹² Children's Hospital of Colorado, Aurora, CO.
¹³ US Food and Drug Administration , Silver Spring, MD.
¹⁴ Arkansas Children's Hospital, Little Rock, AR.
¹⁵ Medical University of Vienna, Austria.
¹⁶ University of Toronto, Canada.
¹⁷ Boston Children's Hospital, Boston, MA.
¹⁸ US National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
¹⁹ Janssen Pharmaceuticals, Raritan, NJ.
²⁰ Novartis Pharmaceuticals, East Hanover, NJ.
²¹ Children's Hospital of Los Angeles, CA.
²² Duke University and the Duke Clinical Research Institute, Durham, NC kevin.hill@duke.edu.

Rachel D Torok et al. J Am Heart Assoc. 2018.

. 2018 Feb 10;7(4):e007283.

doi: 10.1161/JAHA.117.007283.

¹ Duke University and the Duke Clinical Research Institute, Durham, NC.
² Vanderbilt University Medical Center, Nashville, TN.
³ Medical University of South Carolina, Charleston, SC.
⁴ AstraZeneca, Gaithersburg, MD.
⁵ Bayer AG, Whippany, NJ.
⁶ Daiichi Sankyo, Parsippany, NJ.
⁷ Columbia University Medical Center, New York, NY.
⁸ Nationwide Children's Hospital, Columbus, OH.
⁹ Parent Project Muscular Dystrophy, Middletown, OH.
¹⁰ Bristol-Myers Squibb, Princeton, NJ.
¹¹ Albert Einstein College of Medicine, New York, NY.
¹² Children's Hospital of Colorado, Aurora, CO.
¹³ US Food and Drug Administration , Silver Spring, MD.
¹⁴ Arkansas Children's Hospital, Little Rock, AR.
¹⁵ Medical University of Vienna, Austria.
¹⁶ University of Toronto, Canada.
¹⁷ Boston Children's Hospital, Boston, MA.
¹⁸ US National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
¹⁹ Janssen Pharmaceuticals, Raritan, NJ.
²⁰ Novartis Pharmaceuticals, East Hanover, NJ.
²¹ Children's Hospital of Los Angeles, CA.
²² Duke University and the Duke Clinical Research Institute, Durham, NC kevin.hill@duke.edu.

No abstract available

Keywords: clinical trial; drug development; outcomes; pediatric cardiology; regulation.

References

1. Wilson JT. An update on the therapeutic orphan. Pediatrics. 1999;104:585–590. - PubMed
1. Caldwell PH, Murphy SB, Butow PN, Craig JC. Clinical trials in children. Lancet. 2004;364:803–811. - PubMed
1. United States Food and Drug Administration Pediatric Product Development. Available at: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResource.... Accessed June 30, 2017.
1. European Medicines Agency Paediatric Regulation. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_li.... Accessed April 26, 2016.
1. Committee on Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA); Board on Health Sciences Policy; Institute of Medicine ; Field MJ, Boat TF, editors. Safe and Effective Medicines for Children. Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. Washington, DC: National Academies Press; 2012. - PubMed